Up to 50% of oncology molecules that fail in the clinic are due to a lack of efficacy. To improve the odds of clinical success, improved study design methods and more predictive models are needed to identify responsive patient populations and ultimately make better informed decisions before entering clinical trials.
As part of our Tech Talk series In Vivo Solutions and Models for Oncology Drug Development, Dr. Sheng Guo covers the fundamentals of designing Mouse Clinical Trials (MCTs), how to optimally evaluate drug efficacy, and more!
Sheng Guo, PhD, VP of Data Science & Bioinformatics, Crown Bioscience
Dr. Sheng Guo joined Crown Bioscience in 2011 to build up the bioinformatics capabilities, and is currently VP of Data Science & Bioinformatics. Dr. Guo previously worked at Syngenta and Boehringer Ingelheim Pharmaceuticals. He has extensive expertise in tumor model genomics, preclinical statistics, predictive biomarker discovery, NGS-based product design, multi-omics analysis, and industrial software development. Dr. Guo received his PhD in Genomics and Computational Biology from the University of Pennsylvania, and BSc in Biochemistry from Nankai University.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-09-19
2022-07-08
landing_page
Integrated Solutions - MCT